Status:
RECRUITING
LANDscape MApping of Epitopes and T Cell Receptors for Selected Cancers
Lead Sponsor:
University Health Network, Toronto
Conditions:
Solid Tumor
Eligibility:
All Genders
18+ years
Brief Summary
This is a correlative research project aimed at characterizing the T cell mediated immune responses to hepatocellular carcinoma (HCC), as well as Epstein-Barr virus (EBV)- and human papillomavirus (HP...
Detailed Description
The cloning of genes encoding the T cell receptor (TCR), the identification of tumor-associated antigens and the subsequent characterization of the first HLA-restricted T cell-defined antigenic epitop...
Eligibility Criteria
Inclusion
- Patients with a histological or cytological diagnosis of:
- EBV-related malignancies (e.g. nasopharyngeal cancer)
- HPV-related malignancies, including squamous cell carcinoma of the head and neck, cervix, vulva or anal canal. HPV positivity is required for squamous cell cancers of the head and neck.; p16 positivity as a surrogate for HPV testing is acceptable. HPV positivity is not required for cervix, vulva or anal canal cancer.
- For cancers of the anal canal, late stage distant metastatic tumor tissue is preferred. However, early stage primary site tissue is acceptable, if the tissue can be procured without contamination by intestinal microbiota.
- For HCC, only patients who have above UHN institutional upper limit of normal levels of alpha-fetoprotein (AFP) in serum will be eligible. The diagnosis of HCC should be made based on standard of care with or without tumor tissue confirmation.
- Patients must be ≥ 18 years old.
- Patients must have provided voluntary written informed consent.
Exclusion
- 1\. Any condition that, in the opinion of the Investigator, would interfere with patient safety, or evaluation of the collected specimens and interpretation of study results.
Key Trial Info
Start Date :
November 30 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 28 2026
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT04665388
Start Date
November 30 2020
End Date
February 28 2026
Last Update
July 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9